NCT03467360View on ClinicalTrials.gov

Phase I Trial of CArbonic Anhydrase Inhibition in Combination with Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 2, 2019

Primary Completion Date

October 27, 2026

Study Completion Date

April 27, 2027

Conditions
Small Cell Lung Cancer
Interventions
DRUG

acetazolamide in combination with platinum and etoposide-based radiochemotherapy

Radiation therapy will be combined with platinum and etoposide-based chemotherapy combined with 3-6 tablets per day of acetazolamide during the entire course of therapy (dosage appropriate to the inclusion phase).

DRUG

acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC

acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC

Trial Locations (1)

06189

RECRUITING

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

Centre Antoine Lacassagne

OTHER

NCT03467360 - Phase I Trial of CArbonic Anhydrase Inhibition in Combination with Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma | Biotech Hunter | Biotech Hunter